Semaglutide Before and After Blood Work: What to Test and When

GLP-1 Before-and-After Blood Work: What to Test and When

GLP-1 receptor agonist medications (semaglutide, tirzepatide, and similar) primarily target blood sugar and appetite regulation, but the markers worth tracking extend beyond glucose. This page covers what to test before starting, when to retest, and how to read the change, not dosing, cycling, or where to source the medication.

AI-curated · Expert-attributed

Compiled by AI from the named experts’ own public statements, with every figure attributed to its source. These are individual expert protocols, not clinical guidelines or FixFirst medical advice. Evidence & methodology

Baseline-then-retest framework Covers HbA1c, insulin, lipids, and liver enzymes What to test, not how to dose

Baseline first, then retest on a schedule that matches each marker

Different markers move on different timelines. Testing everything again at week 2 wastes a draw on markers that haven't had time to change; waiting a year misses the early signal on markers that move fast.

This page is part of FixFirst's Longevity blood markers series. It covers the testing framework only: what to check before starting a GLP-1 medication, what to recheck and when, and how to read the direction of change. It does not cover dosing schedules, titration, or where to obtain the medication, questions for your prescribing physician.

A baseline draw before starting establishes where you're measuring from. Without it, a result three months into treatment tells you the current number but not how much moved or how fast, which matters for deciding whether the medication and any accompanying lifestyle changes are working as expected.

HbA1c reflects a 3-month rolling average, so retesting before 10–12 weeks measures an average that's still mostly your pre-treatment blood sugar, covered in more depth on the HbA1c blood test guide. Fasting insulin and lipids can shift faster, within 4–8 weeks, and liver enzymes typically take longer to move meaningfully unless the starting values were elevated.

What to test, and the retest cadence

Four clusters. GLP-1 receptor agonists are approved to lower blood sugar and reduce body weight; the lipid and liver changes below are downstream of those primary effects and vary by individual.

Cluster 1 of 3

Blood sugar control

GLP-1 receptor agonists work by enhancing glucose-dependent insulin secretion and slowing gastric emptying, so blood sugar markers are the most direct place to look for change.

Core Usually in a standard panel Ask Request specifically

Core

Fasting Glucose

A useful baseline snapshot, but a single fasting reading can miss the fuller picture of glycemic control, especially early in treatment. The ADA prediabetes range starts at 100 mg/dL.

Ask

HbA1c

The 3-month rolling average, and the marker to retest no sooner than 10–12 weeks after starting, since testing earlier mostly reflects the pre-treatment average. This is the primary marker GLP-1 therapy is indicated to move for people with elevated blood sugar.

Ask

Fasting Insulin

Not part of a standard panel, but useful as a baseline if insulin resistance is a concern, since it can shift within weeks as glucose-dependent insulin secretion improves. Covered in more depth on the fasting insulin guide.

Cluster 2 of 3

Lipids

Weight loss and improved glycemic control are both independently associated with favorable lipid changes, so a repeat lipid panel is a reasonable checkpoint alongside blood sugar markers.

Core Usually in a standard panel Ask Request specifically

Core

Triglycerides

Often one of the faster-moving lipid markers, since triglycerides respond to both reduced caloric intake and improved insulin sensitivity. The standard clinical flag is above 150 mg/dL.

Core

HDL & LDL

Worth rechecking alongside triglycerides as part of a standard lipid panel. Change here tends to track with the degree of weight loss and dietary shifts alongside the medication, not the medication alone.

Cluster 3 of 3

Liver

GLP-1 medications are studied for their effect on non-alcoholic fatty liver disease, since weight loss and improved insulin sensitivity both reduce hepatic fat.

Core Usually in a standard panel Ask Request specifically

Core

ALT

Worth a baseline check if starting values are elevated, since hepatic fat reduction from weight loss can lower ALT over months, not weeks. Standard labs flag above roughly 40–56 U/L depending on the lab.

Core

AST

Read alongside ALT rather than alone; the ratio between the two helps distinguish a fatty-liver pattern from other causes of elevation.

Frequently asked questions

What blood tests should I get before starting a GLP-1 medication?

A reasonable baseline panel covers fasting glucose, HbA1c, a standard lipid panel (triglycerides, HDL, LDL), and liver enzymes (ALT, AST). Your prescribing physician may add others depending on your history, such as fasting insulin, kidney function, or a pregnancy test where relevant. This is a testing checklist, not medical advice on whether to start the medication.

How soon after starting semaglutide should I retest HbA1c?

HbA1c reflects roughly the prior 3 months, so retesting before 10–12 weeks mostly captures your pre-treatment average rather than the new one. Fasting glucose and fasting insulin can be worth checking sooner if you want an earlier read, since they reflect current, not averaged, blood sugar status.

Will my cholesterol change on a GLP-1 medication?

Triglycerides in particular often move alongside weight loss and improved insulin sensitivity, both associated with GLP-1 therapy. HDL and LDL change varies more by individual and by accompanying diet changes. A repeat lipid panel at your next scheduled retest gives you an actual read rather than a guess.

Does semaglutide affect liver enzymes?

GLP-1 medications are studied for their effect on non-alcoholic fatty liver disease, and weight loss generally reduces hepatic fat over months. If ALT or AST were elevated at baseline, that's the more informative comparison point than starting from a normal reading. Liver enzymes typically move on a slower timeline than glucose markers.

What if my blood sugar markers don't improve as expected?

That's a conversation for your prescribing physician, not something to self-diagnose from a lab report. Bring your before-and-after results to your next appointment; the trend across multiple markers (glucose, HbA1c, weight, and any symptoms) gives a fuller picture than any single number.

Once you have before-and-after results

Comparing two lab reports side by side is harder than it sounds when the layout or lab changes between draws. FixFirst reads both against the same clinical thresholds.

Upload to FixFirst

Get your top 3 priorities ranked in 45 seconds

Upload either report, or both, and FixFirst checks all 86 markers against standard clinical thresholds, adjusted for your sex and context.

Upload My Report →

More longevity marker pages

See the full Longevity section

Peter Attia's full panel, Andrew Huberman's markers, and optimal IGF-1, each attributed to its source.

Browse the Longevity section

GLP-1 Before-and-After Blood Work: What to Test and When

Baseline first, then retest on a schedule that matches each marker

What to test, and the retest cadence

Frequently asked questions

Once you have before-and-after results

Compare your before-and-after results against the same clinical thresholds.